UC Hastings College of the Law is pleased to announce the appointment of Dr. Alfred C. Server as an Affiliated Scholar. Affiliated Scholars bring either an academic or a practical perspective to enrich an area in which UC Hastings has a focus. Dr. Server, a lawyer and a doctor who has built a prominent career in the biotechnology industry, will work primarily with UC Hastings’ Institute for Innovation Law.
“Dr. Server brings a wealth of experience from the real world of science and innovation,” says Robin Feldman, Professor of Law and Director of the Law and Bioscience Project, “as well as an impressive record of publications in areas that impact Silicon Valley companies. His latest article, Contract-Based Post-Sale Restrictions on Patented Products Following Quanta, has just been published by the UC Hastings Law Journal.
“Recently,” Feldman continues, “we were discussing a thorny issue that one of the companies in our BioTech Startup Clinic is facing. The student working with the startup was completely at a loss about how to resolve it. I smiled and told him that the nation's leading authority on that issue was sitting right down the hall—Dr. Fred Server.”
UC Hastings’s Institute for Innovation Law is interested in partnering with great minds in the diverse fields that affect innovation – from scientists, to technology experts, to inventors and those who advise them. As an Affiliated Scholar, Dr. Server will participate in campus events and engage in intellectual exchange and dialogue with the Institute and UC Hastings faculty. “We are honored to have Dr. Server join our community,” says Associate Dean for Academic Research William S. Dodge.
Alfred C. Server was a partner in the Technology Transactions and Licensing Practice Group with WilmerHale LLP from 1993 until 2012. He received an AB degree, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa; he also holds a JD from Harvard Law School and an MD and a PhD (neurological sciences) from Stanford University. His medical training includes a prestigious internship at Peter Bent Brigham Hospital (a predecessor of Brigham and Women’s Hospital), a neurology residency at Johns Hopkins Hospital, and post-doctoral fellowships in neurovirology, genetics, and molecular biology at Johns Hopkins University, Harvard University and the Massachusetts General Hospital. Dr. Server was also a founder and the research director of a biotechnology company.
At WilmerHale, Dr. Server represented the firm's clients in some of the most significant and highly regarded strategic alliance transactions in the lifesciences industry, including Incyte Corporation’s recent $2 billion licensing deals with Novartis and Eli Lilly and Company relating to the development and commercialization of drug candidates for the treatment of cancer and inflammation.
Dr. Server was also involved in the establishment of The SNP Consortium, a nonprofit organization made up of 10 of the world's leading pharmaceutical companies and a British charity. The consortium was established to identify and develop a map of genetic variation in the human genome, which has been made publicly available.